BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™...
SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™...
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools.
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools.
Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development.
Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development.
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease.
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease.
Newly issued patents in Australia and Japan cover the company's Artero™ E-IVL and Sola™ L-IVL platforms as FastWave advances toward peripheral and coronary IDE trials.
Newly issued patents in Australia and Japan cover the company's Artero™ E-IVL and Sola™ L-IVL platforms as FastWave advances toward peripheral and coronary IDE trials.
The eLym System is an investigational catheter-based device for treating patients with acute decompensated heart failure (ADHF) by supporting lymphatic drainage.
The eLym System is an investigational catheter-based device for treating patients with acute decompensated heart failure (ADHF) by supporting lymphatic drainage.
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
Pradyumna Agasthi, MD; Kaitlyn Krebushevski, MD; Allison K. Cabalka, MD; Jason H. Anderson, MD
The authors report use of a thoracic branch endoprostheses to treat recurrent coarctation of the aorta in a patient presenting with an aortic pseudoaneurysm and a peak-to-peak gradient of 29 mm Hg between the ascending and descending aorta.
The authors report use of a thoracic branch endoprostheses to treat recurrent coarctation of the aorta in a patient presenting with an aortic pseudoaneurysm and a peak-to-peak gradient of 29 mm Hg between the ascending and descending aorta.
A 59-year-old woman with end-stage renal disease undergoing maintenance hemodialysis through sequential right and left internal jugular venous catheters presented with progressive facial and neck swelling, dyspnea, and a non-functioning,...
A 59-year-old woman with end-stage renal disease undergoing maintenance hemodialysis through sequential right and left internal jugular venous catheters presented with progressive facial and neck swelling, dyspnea, and a non-functioning,...
Eric J. Kim, MD, MBE; Yash Prakash, MD; Hassan Beesley, MD; Grigory Manyak, MD; Mihir Prakash; Lakshay Chopra, MD; Akarsh Sharma, MD; Carlo Mannina, MD; George D. Dangas, MD, PhD; Lucy M. Safi, DO; Sahil Khera, MD, MPH; Samin K. Sharma, MD; Annapoorna S. Kini, MD; Gilbert H.L. Tang, MD, MSc, MBA; Stamatios Lerakis, MD, PhD
The study examined the association between chronic kidney disease (CKD) and right-sided extravalvular damage within low-flow, low-gradient aortic stenosis and across each stage of CKD.
The study examined the association between chronic kidney disease (CKD) and right-sided extravalvular damage within low-flow, low-gradient aortic stenosis and across each stage of CKD.
In this 2026 SCAI session, Dr Saibal Kar explored how LAAO is moving beyond its traditional use in patients with nonvalvular AFib who are ineligible for anticoagulation.
In this 2026 SCAI session, Dr Saibal Kar explored how LAAO is moving beyond its traditional use in patients with nonvalvular AFib who are ineligible for anticoagulation.
The randomized EQUAL trial showed that smartwatch-based atrial fibrillation (AF) screening increased detection rates more than 4-fold vs usual care in older adults with elevated stroke risk.
The randomized EQUAL trial showed that smartwatch-based atrial fibrillation (AF) screening increased detection rates more than 4-fold vs usual care in older adults with elevated stroke risk.
Ping Hu, MD; Xin-yu Wang, MD; Ming Qi, MD; Jie Wang, MD; Xiao-Jing Ma, PhD
A 55-year-old man presented with medically controlled essential hypertension and a history of abdominal aortic aneurysm stenting 2 years prior who presented with a 3-month history of left lower extremity fatigue on exertion.
A 55-year-old man presented with medically controlled essential hypertension and a history of abdominal aortic aneurysm stenting 2 years prior who presented with a 3-month history of left lower extremity fatigue on exertion.
Eileen Galvani, MD; Oludamilola Akinmolayemi, MD, MPH; Srivatsan Swaminathan, BS; Carlo Mannina, MD; Sahil Khera, MD, MPH; Lucy M. Safi, DO; Gilbert H.L. Tang, MD, MSc, MBA; Samin K. Sharma, MD; Annapoorna S. Kini, MD; Stamatios Lerakis, MD, PhD
The authors hypothesized that among patients with low-flow aortic stenosis (LFAS), outcomes differ based on sex and subtype of LFAS: classical, paradoxical, and high gradient.
The authors hypothesized that among patients with low-flow aortic stenosis (LFAS), outcomes differ based on sex and subtype of LFAS: classical, paradoxical, and high gradient.
A 12-year-old boy with a case of disseminated tuberculosis who was on guideline-directed oral antitubercular therapy presented to the outpatient clinic with worsening exertional dyspnea for the past 2 months.
A 12-year-old boy with a case of disseminated tuberculosis who was on guideline-directed oral antitubercular therapy presented to the outpatient clinic with worsening exertional dyspnea for the past 2 months.
